A. P. Semenov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. P. Semenov has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- A. G. Yusufov
Pirogov Russian National Research Medical University ; “Kommunarka” Moscow Multidisciplinary Clinical Centre
3 shared publications - R. I. Gouspanov
Pirogov Russian National Research Medical University ; “Kommunarka” Moscow Multidisciplinary Clinical Centre
3 shared publications - Sergey Vladislavovich Kotov
N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Moscow Multidisciplinary Clinical Centre “Kommunarka
3 shared publications - A. D. Bolotov
Pirogov Russian National Research Medical University (Pirogov Medical University)
1 shared publication - D. A. Bogdanov
«Kommunarka» Moscow Multidisciplinary Clinical Centre
1 shared publication - S. A. Pulbere
Pirogov Russian National Research Medical University (Pirogov Medical University)
1 shared publication
Latest Publications
- Open Access
- 2 March 2025
- Published by Rostov State Medical University in Urology Herald
- Vol. 13 (1) , 48-55
Affective disorders before and after laser enucleation of the prostate
Introduction. Lower urinary tract symptoms (LUTS), sexual dysfunction and psychological disorders coexist in the lives of older men. Evaluation of the prevalence of mood disorders and sexual dysfunction after surgical treatment is important to ensure a high quality of life for patients with LUTS.Objective. To analyse the incidence and severity of affective disorders in patients before and after laser enucleation of the prostate and to determine their association with LUTS and erectile dysfunction. Materials & methods. The study included 136 patients with benign prostatic hyperplasia treated with laser enucleation between 2018 and 2023. All the male participants were sexually active, and their erectile function was assessed at 11 points or higher according to the IIEF-5 scale. In addition to standard examination methods, all patients completed the IPSS, IIEF-5, and HADS questionnaires prior to surgery and 18 months postoperatively. The first stage of the study involved an investigation into the prevalence and severity of affective disorders both before and after surgical intervention, as well as determining their correlation with LUTS. The second stage focused on examining the relationship between affective disorders and sexual dysfunction. Patients were categorized into two groups based on the absence or presence of negative influence of LUTS on their quality of sexual life: group 1 (n = 70) — no influence, group 2 (n = 66) — influence is present.Results. Anxiety and depressive disorders of varying severity were found in 48 (35.3%) and 46 (33.8%) patients, respectively. It was found that the severity of both anxiety (r = 0.574; p < 0.001) and depressive disorders before surgical treatment correlated with LUTS (r = 0.590; p < 0.001), but after surgical treatment only anxiety disorder scores had a correlation with LUTS (r = 0.742; p < 0.001), and with irritative symptoms (r = 0.475; p < 0.001). Group 2 patients had lower IIEF-5 scores (18.0 vs. 21.0 points; p < 0.001) and were more likely to have anxiety and depressive disorders before surgical treatment (45.7 and 44.3% vs. 22.8 and 22.7%; p < 0.05), with significant improvement in erectile function and affective status after surgery, in contrast to group 1 patients, whose IIEF-5 scores and incidence of affective disorders did not change significantly.Conclusion. Patients with a predominantly irritative LUTS profile and a negative impact of urinary disturbances on sexual life are more susceptible to anxiety and depressive disorders. Consequently, evaluating their affective state is essential when treating men with LUTS to enhance their quality of life.
- 2 March 2025
- Published by Rostov State Medical University in Urology Herald
- Vol. 13 (1) , 48-55
Open AccessAffective disorders before and after laser enucleation of the prostate
Introduction. Lower urinary tract symptoms (LUTS), sexual dysfunction and psychological disorders coexist in the lives of older men. Evaluation of the prevalence of mood disorders and sexual dysfunction after surgical treatment is important to ensure a high quality of life for patients with LUTS.Objective. To analyse the incidence and severity of affective disorders in patients before and after laser enucleation of the prostate and to determine their association with LUTS and erectile dysfunction. Materials & methods. The study included 136 patients with benign prostatic hyperplasia treated with laser enucleation between 2018 and 2023. All the male participants were sexually active, and their erectile function was assessed at 11 points or higher according to the IIEF-5 scale. In addition to standard examination methods, all patients completed the IPSS, IIEF-5, and HADS questionnaires prior to surgery and 18 months postoperatively. The first stage of the study involved an investigation into the prevalence and severity of affective disorders both before and after surgical intervention, as well as determining their correlation with LUTS. The second stage focused on examining the relationship between affective disorders and sexual dysfunction. Patients were categorized into two groups based on the absence or presence of negative influence of LUTS on their quality of sexual life: group 1 (n = 70) — no influence, group 2 (n = 66) — influence is present.Results. Anxiety and depressive disorders of varying severity were found in 48 (35.3%) and 46 (33.8%) patients, respectively. It was found that the severity of both anxiety (r = 0.574; p < 0.001) and depressive disorders before surgical treatment correlated with LUTS (r = 0.590; p < 0.001), but after surgical treatment only anxiety disorder scores had a correlation with LUTS (r = 0.742; p < 0.001), and with irritative symptoms (r = 0.475; p < 0.001). Group 2 patients had lower IIEF-5 scores (18.0 vs. 21.0 points; p < 0.001) and were more likely to have anxiety and depressive disorders before surgical treatment (45.7 and 44.3% vs. 22.8 and 22.7%; p < 0.05), with significant improvement in erectile function and affective status after surgery, in contrast to group 1 patients, whose IIEF-5 scores and incidence of affective disorders did not change significantly.Conclusion. Patients with a predominantly irritative LUTS profile and a negative impact of urinary disturbances on sexual life are more susceptible to anxiety and depressive disorders. Consequently, evaluating their affective state is essential when treating men with LUTS to enhance their quality of life.
- Open Access
- 29 April 2024
- Published by Rostov State Medical University in Urology Herald
- Vol. 12 (2) , 43-57
Efficacy of Phlogenzyme® in men following transurethral laser enucleation of prostate hyperplasia: results of a randomized trial
Introduction. The most advanced and effective method of surgical treatment for benign prostatic hyperplasia (BPH) is transurethral laser enucleation of the prostate (tLEP). Recently, there has been a growing interest in exploring new approaches to reduce the risk of complications following tLEP.Objective. To evaluate the efficacy of using Phlogenzym® as part of a comprehensive treatment plan for patients following tLEP to reduce dysuria (urinary discomfort), leukocyturia (white blood cells in urine), and prevent infectious and fibrosis-related complications.Materials & methods. An open-label, randomized trial enrolled 105 patients undergoing tLEP. The patients were randomly assigned to two groups: the study group (n=50) received standard postoperative care in combination with Phlogenzym® for 30 days, while the control group (n=55) received standard care (α1-adrenergic blocker for 28 days) only. uring the follow-up period, which lasted for 1, 3, and 6 months postoperatively, complaints were evaluated using the IPSS-QoL, and IIEF-5 questionnaires, as well as indicators of urinalysis and urine culture, prostate volume measurements, residual urine volume, and uroflowmetry data.Results. Among all patients, the median preoperative values for prostate volume, IPSS, QoL score, and median peak urine flow rate were 90 cc, 18 points, 5 points, and 7.9 mL/s, respectively, with no significant differences between the groups. One month after surgery, in the study group, there was a more significant decrease in prostate volume (57% vs. 41%), although this difference was not statistically significant (p > 0.05). At the 6-month follow-up, bacteriuria was less common in the study group (42% vs. 67%), and there was a consistent trend toward a reduction in the incidence of fibrous complications, although these differences were not statistically significant either (p > 0.05). No adverse events occurred during the follow-up period.Conclusion. Our experience suggests that the use of Phlogenzym® is safe during the postoperative period following tLEP surgery. The use of this drug leads to a reduction in prostate volume postoperatively and significantly reduces the bacteriuria by the six-month follow-up. Additionally, there is a persistent positive trend towards reducing the overall incidence of fibrotic complications in the surgical site. The results achieved and the absence of significant side effects characterize Phlogenzym® as having a favorable clinical profile.
- 29 April 2024
- Published by Rostov State Medical University in Urology Herald
- Vol. 12 (2) , 43-57
Open AccessEfficacy of Phlogenzyme® in men following transurethral laser enucleation of prostate hyperplasia: results of a randomized trial
Introduction. The most advanced and effective method of surgical treatment for benign prostatic hyperplasia (BPH) is transurethral laser enucleation of the prostate (tLEP). Recently, there has been a growing interest in exploring new approaches to reduce the risk of complications following tLEP.Objective. To evaluate the efficacy of using Phlogenzym® as part of a comprehensive treatment plan for patients following tLEP to reduce dysuria (urinary discomfort), leukocyturia (white blood cells in urine), and prevent infectious and fibrosis-related complications.Materials & methods. An open-label, randomized trial enrolled 105 patients undergoing tLEP. The patients were randomly assigned to two groups: the study group (n=50) received standard postoperative care in combination with Phlogenzym® for 30 days, while the control group (n=55) received standard care (α1-adrenergic blocker for 28 days) only. uring the follow-up period, which lasted for 1, 3, and 6 months postoperatively, complaints were evaluated using the IPSS-QoL, and IIEF-5 questionnaires, as well as indicators of urinalysis and urine culture, prostate volume measurements, residual urine volume, and uroflowmetry data.Results. Among all patients, the median preoperative values for prostate volume, IPSS, QoL score, and median peak urine flow rate were 90 cc, 18 points, 5 points, and 7.9 mL/s, respectively, with no significant differences between the groups. One month after surgery, in the study group, there was a more significant decrease in prostate volume (57% vs. 41%), although this difference was not statistically significant (p > 0.05). At the 6-month follow-up, bacteriuria was less common in the study group (42% vs. 67%), and there was a consistent trend toward a reduction in the incidence of fibrous complications, although these differences were not statistically significant either (p > 0.05). No adverse events occurred during the follow-up period.Conclusion. Our experience suggests that the use of Phlogenzym® is safe during the postoperative period following tLEP surgery. The use of this drug leads to a reduction in prostate volume postoperatively and significantly reduces the bacteriuria by the six-month follow-up. Additionally, there is a persistent positive trend towards reducing the overall incidence of fibrotic complications in the surgical site. The results achieved and the absence of significant side effects characterize Phlogenzym® as having a favorable clinical profile.
- Open Access
- 22 December 2023
- Published by Rostov State Medical University in Urology Herald
- Vol. 11 (4) , 128-140
Effect of endoscopic enucleation of the prostate on erectile and ejaculatory function
Benign prostatic hyperplasia (BPH) is a highly prevalent condition in older men, often associated with both lower urinary tract symptoms (LUTS) and reduced quality of sexual life. During the past three decades, researchers have focused on improving new operative techniques to reduce complications of traditional surgery for BPH, such as urethral stricture, stress urinary incontinence. Surgeons have increased interest in investigating the relationship between surgical treatment and postoperative sexual dysfunction such as erectile and ejaculatory dysfunction, as the demand to minimise adverse events has become a concern for more patients. In view of the above, this paper aims to systematise information on the quality of sexual life of patients after surgical treatment of BPH. This work has shown that this problem remains topical to nowadays. It is noteworthy that only a limited number of well-designed, randomised studies exist on this issue. This is mainly due to the unavailability of a uniform methodology for assessing sexual function in surgically treated BPH-patients.
- 22 December 2023
- Published by Rostov State Medical University in Urology Herald
- Vol. 11 (4) , 128-140
Open AccessEffect of endoscopic enucleation of the prostate on erectile and ejaculatory function
Benign prostatic hyperplasia (BPH) is a highly prevalent condition in older men, often associated with both lower urinary tract symptoms (LUTS) and reduced quality of sexual life. During the past three decades, researchers have focused on improving new operative techniques to reduce complications of traditional surgery for BPH, such as urethral stricture, stress urinary incontinence. Surgeons have increased interest in investigating the relationship between surgical treatment and postoperative sexual dysfunction such as erectile and ejaculatory dysfunction, as the demand to minimise adverse events has become a concern for more patients. In view of the above, this paper aims to systematise information on the quality of sexual life of patients after surgical treatment of BPH. This work has shown that this problem remains topical to nowadays. It is noteworthy that only a limited number of well-designed, randomised studies exist on this issue. This is mainly due to the unavailability of a uniform methodology for assessing sexual function in surgically treated BPH-patients.